Amphastar Pharmaceuticals, Inc.(AMPH)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Amphastar Pharmaceuticals, Inc. (AMPH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMPH at 50.5/100 on a 32-signal composite quality model, placing it at rank #1,598 of 2,962 stocks — the bottom half of the AI-ranked universe. AMPH scores in the top quartile across earnings quality (86.0). Areas of concern include institutional flow (4.5) and revenue growth (36.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Amphastar Pharmaceuticals, Inc. reports quarterly revenue of $183.9M, net income of $30.3M, free cash flow of $42.7M. Top institutional holders of AMPH by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, STATE STREET, based on the most recent SEC filings. AMPH trades on the Nasdaq exchange and files with the SEC under CIK 1297184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amphastar Pharmaceuticals, Inc. directly from SEC EDGAR.